Datasea Intelligent Technology is progressing with compliance and administrative steps for U.S. FDA establishment registration and device listing of its acoustic brain-computer interface (BCI) product. This product integrates acoustic stimulation, bone-conduction neuromodulation, EEG signal acquisition, and AI-assisted health management, targeting non-invasive neurological health applications. The move is part of Datasea's international strategy to expand its acoustic medical and BCI product portfolio, aiming to offer safer and more accessible alternatives to traditional invasive BCI technologies. The company has not yet received FDA approval and cautions that regulatory processes may face uncertainties, but it plans to keep investors updated on material progress.
Christopher Derrick, known for writing on Star Trek: Picard and The Equalizer, premieres his first film as sole writer-director, Moral Dirt, at the Academy Award® Qualifying LA Shorts International Film Festival on August 3, 2026. The 15-minute psych...
Arcutis Biotherapeutics has appointed Chris Peetz to its Board of Directors as of July 15, 2026. Peetz brings extensive experience leading biopharmaceutical companies through growth phases, product development, and strategic acquisitions. His additio...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
